In order to search for new approaches to treat glioma, intranasal administration has been proposed as an alternative route to deliver drugs into the brain. Among the drug alternatives, kaempferol (KPF) has been reported to induce glioma cell death. This study aimed to prepare nanoemulsions containing KPF with and without chitosan to investigate their potential for brain delivery following intranasal administration, and to evaluate their antitumor activity against glioma cells. KPF-loaded nanoemulsion (KPF-NE) and KPF-loaded mucoadhesive nanoemulsion (KPF-MNE) were prepared by high-pressure homogenization technique and were characterized for their globule size, zeta potential, drug content, pH, viscosity, mucoadhesive strength and morphology. KPF from KPF-MNE showed significantly higher permeation across the mucosa in ex vivo diffusion studies. Histopathological examination suggests both nanoemulsions to be safe for the nasal mucosa and able to preserve KPF antioxidant capability. KPF-MNE enhanced significantly the amount of drug into rat's brain following intranasal administration (5-and 4.5-fold higher than free drug and KPF-NE, respectively). In addition, KPF-MNE reduced C6 glioma cell viability through induction of apoptosis to a greater extent than either free KPF or KPF-NE. The mucoadhesive nanoemulsion developed for intranasal administration may be a promising system for delivery to the brain, and KPF-MNE is a candidate for further antiglioma trials.
Introduction
Kaempferol (KPF; 3,4′,5,7-tetrahydroxyflavone) is a natural flavonol present in different plant species, found abundantly in edible plants (broccoli, apples, strawberries and beans) and common medicinal plants (Aloe vera, Ginkgo biloba, Rosmarinus officinalis, Crocus sativus L., Hypericum perforatum L., Equisetum spp,) (Calderon-Montano et al., 2011; Sultana and Anwar, 2008) .
KPF has been described to present anti-oxidant, anti-inflammatory, neuroprotective and anti-tumor activities (Chen and Chen, 2013; Devi et al., 2015; Lopez-Sanchez et al., 2007) . Recently, research studies have reported KPF presenting anti-cancer activity in various cancer cells, including glioma cells (Jeong et al., 2009; Nakatsuma et al., 2010; Seibert et al., 2011; Sharma et al., 2007; Siegelin et al., 2008) . However, its low water solubility and bioavailability are not desired properties of a candidate drug, and limit its application in the clinical field (Barve et al., 2009; Chen et al., 2010; Luo et al., 2012) . In this way, the identification of an appropriate formulation and route of administration is part of the accurate selection and optimization of a candidate drug.
Gliomas are the most common and deadly type of intrinsic brain tumor in adults, of which glioblastoma multiforme (GBM) represents the ultimate grade of malignancy. Despite multimodal therapy (neurosurgical resection, radiotherapy and chemotherapy), the median overall survival of patients with GBM does not exceed 15 months from diagnosis (Stupp et al., 2009 ). The dismal prognosis for GBM is due to its high capacity for proliferation and an infiltrative growth pattern, variability in the tumor histopathology and resistance to radiation-and chemotherapy (Van Meir et al., 2010) . Moreover, another important factor that impairs the development of new therapeutic strategies for treating GBM is the presence of the blood-brain barrier (BBB) , that hampers the drug penetration into the central nervous system (CNS), restricting the glioma therapy and inducing therapy failure (Behin et al., 2003; Van Meir et al., 2010) .
Recognizing the need to improve patient survival, different drug delivery approaches have been studied, and the intranasal route of administration is a strategy that provides a noninvasive method to deliver therapeutic drugs into the brain (Alam et al., 2010) . The intranasal route provides direct and rapid transport of drugs from the nasal cavity to the brain, involving three main pathways: olfactory nerve pathway, transport via the trigeminal nerves, and the systemic pathway (Illum, 2000; Pardeshi and Belgamwar, 2013) . Furthermore, this strategy offers painless and efficient drug delivery by circumventing the BBB and avoiding hepatic first-pass metabolism by using the permeable nasal mucosa as a route to the brain (van Woensel et al., 2013) . Nanoemulsions hold great potential in nose-to-brain drug delivery, increasing the absorption and the bioavailability of many water-insoluble compounds by nasal administration. Because of their small diameter, nanoemulsions present large surface area and high free energy, ensuring faster and higher drug permeation through biological membranes. Furthermore, these systems may offer protection from enzymatic and chemical degradation (Comfort et al., 2015; van Woensel et al., 2013) .
To improve the nasal residence time of the formulation and to enhance permeation across the nasal membrane, chitosan has shown great potential, by decreasing mucociliary clearance due to its bioadhesive and permeation-enhancing properties (Casettari and Illum, 2014) . Chitosan is one of the most studied polymers in the area of transmucosal drug delivery. This polycationic polymer is an N-deacetylated product of the polysaccharide chitin, and shows interesting properties, such as biocompatibility, biodegradability, and low local and systemic toxicity (Bernkop-Schnurch and Dunnhaupt, 2012) .
Considering the advantages of nose-to-brain transport afforded by nanoemulsions, the main aims of the present study were to develop a kaempferol-loaded mucoadhesive nanoemulsion (KPF-MNE) and to evaluate both its potential as a delivery system to rat's brain following nasal administration, and its activity against a glioma cell line.
Materials and methods

Materials
KPF (purity greater than 98%) was purchased from ShaanXi HuiKe Botanical (Xi'an, China). Egg-lecithin (Lipoid E-80 s) and medium-chain triglycerides (MCT) were purchased from Lipoid GmbH (Ludwigshafen, Germany). Polysorbate 80 was supplied from Sigma Aldrich (Steinheim, Germany). Chitosan (low molecular weight, degree of deacetylation 75-85%) was purchased from Sigma Aldrich (St Louis, USA). Methanol HPLC grade and Formic Acid 96% were obtained from Tedia (Rio de Janeiro, Brazil). Ultrapure water was obtained from a Milli-Q apparatus (Millipore, Billerica, USA). Porcine heads were purchased from Ouro do Sul Ltda (Harmonia, Brazil). Mucin from porcine stomach was from Sigma Aldrich (Sigma, St. Louis, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin, and 0.5% trypsin/EDTA solution were obtained from Gibco (Gibco BRL, Carlsbad, USA). Gentamicin was obtained from Schering do Brazil (Rio de Janeiro, Brazil). Propidium iodide (PI) and dimethyl sulfoxide (DMSO) were obtained from Sigma (St. Louis, USA). AnnexinV-FITC/PI was obtained from BD Biosciences (San Diego, USA). All other reagents used were of analytical grade.
High-performance liquid chromatography analysis
Quantification of KPF in formulations, nasal mucosa and brain was assessed by high-performance liquid chromatography (HPLC) using the chromatographic conditions previously validated by our research group (Colombo et al., 2017) . In brief, HPLC apparatus consisted of a Shimadzu LC-10A system (Kyoto, Japan) equipped with a model LC-20AT pump, a SPD-20AV UV-vis variable wavelength detector, a DGU-20A5 degasser, a CBM-20A system controller, and an SIL-20A injection valve with a 100 μL loop. Kaempferol was analyzed using a XTerra® RP18 column (250 mm × 4.6 mm, 5 μm particle size). The mobile phase consisted of a 75:25 (v/v) mixture of methanol and 0.1% formic acid in water in isocratic flow at a flow rate of 1.0 mL/min, with detection at 368 nm and temperature of 35°C.
Preparation of nanoemulsion and mucoadhesive nanoemulsion
The kaempferol-loaded nanoemulsion (KPF-NE) was prepared by a high-pressure homogenization technique (Colombo et al., 2017) . The oil phase was prepared by dispersing KPF (0.1% w/w) in 16% (w/w) MCT and 5.0% (w/w) egg-lecithin. The aqueous phase contained 1.0% (w/w) polysorbate 80 and water. First, a coarse emulsion was prepared by the homogenization of both phases using an IKA® Ultra-Turrax T8 mixer (IKA® Works Inc., NC, USA) at 9500 rpm for 1 min. Afterwards, the coarse emulsion was subjected to high-pressure homogenization (EmulsiFlex-C3®, Avestin, Canada) for eight cycles at 750 bar to produce the final nanoemulsion.
The KPF-loaded mucoadhesive nanoemulsion was prepared after the KPF-NE. The nanoemulsion external phase was evaporated under reduced pressure to 75% of the initial volume and then adding the required volume of chitosan solution (1% w/v in 0.1% acetic acid) so the final concentration of polymer in the KPF-MNE was 0.25% (w/v). After addition of the chitosan solution, the KPF-MNE was allowed to homogenize for 10 min with continuous stirring on a magnetic stirrer. Blank nanoemulsion (NE) and blank mucoadhesive nanoemulsion (MNE) were prepared without KPF incorporation.
Characterization of nanoemulsions
Globule size and zeta potential measurements
Globule size and polydispersity index (PDI) were evaluated by photon correlation spectroscopy. Each nanoemulsion was diluted in ultrapure water (1:1000) before measurement. The determination of the zeta potential was performed by eletrophoretic mobility, after dilution of the formulations in 1 mM NaCl (1:1000). All analyses were carried out in triplicate using a Malvern Nano-ZS90® (Malvern Instruments, England) at 25°C.
Transmission electron microscopy (TEM)
Morphology and size of nanoemulsions were studied using transmission electron microscopy (TEM). Before analysis, samples were diluted with ultrapure water, placed on a carbon-coated copper grid (200 mesh) coated with Formvar/carbon, stained with 2.0% uranyl acetate aqueous solution, and examined using a JEM-1200 EXII instrument (JEOL, Tokyo, Japan).
Viscosity, pH and refractive index (RI)
Nanoemulsion viscosity and rheological behavior were determined in a rotational viscosimeter (Brookfield LVDVII + Pro model, Middleboro, USA) equipped with a ULA spindle. For the determinations, samples (16 mL, n = 3) were conditioned in a Brookfield device coupled to a thermostated circulating water bath at 25 or 34°C. The pH of formulations was measured at room temperature using a calibrated digital pH meter (Digimed, São Paulo, Brazil) by placing 10 mL of each formulation in a beaker. The refractive index (RI) of formulations was determined in triplicate using an Abbe-type refractometer in the presence of visible light at ambient temperature (USP, 2011).
KPF content and association efficiency (%AE)
KPF content in nanoemulsions was assayed by HPLC as previously described, after sample dilution in methanol to obtain a theoretical concentration of 5.0 µg/mL. To show the improvement in KPF solubility, saturation solubility in water was performed as follows: an excess amount of KPF was added to 2 mL of distilled water. The samples were sealed in triplicate and shaken for 48 h at 37°C. The supernatant was filtered through a Millipore filter (pore size 0.45 μm), and assayed by HPLC. In order to determine the %AE, the free KPF content in the nanoemulsions was determined by measuring the nonincorporated KPF present in the aqueous phase using HPLC after ultrafiltration/centrifugation with Microcon® centrifugal filter devices (100,000 NMWL; Millipore, USA) for 15 min at 15,000 rpm. Values of %AE for each nanoemulsion, after triplicate measurements, were calculated using Eq.
(1): = − × %AE (total drug free drug)/total drug 100
(1) 2.5. In vitro DPPH assay for antioxidant activity
The antioxidant activity of the optimized formulations was compared with methanolic KPF solution using the DPPH assay method. The test was based on the free-radical scavenging activity of 2,2-diphenyl-1-picrylhydrazyl (DPPH), a stable nitrogen-centered free radical (Caddeo et al., 2013) . A methanolic DPPH solution (0.004% w/v) was prepared, of which 3.9 mL were mixed with either 0.1 mL KPF nanoemulsions (KPF-NE or KPF-MNE) or 0.1 mL KPF solution (1 mg/mL in methanol) or blank nanoemulsions. Absorbance was measured after 60 min at 515 nm using methanol as blank (without the drug). The percentage inhibition was calculated using Eq. (2):
where A 0 is the absorbance of the blank, and A 1 is the absorbance of the drug solution or nanoemulsion. All experiments were performed in triplicate.
Ex vivo diffusion study
An ex vivo diffusion study of formulations was determined using a Franz diffusion cell through a freshly isolated pig nasal mucosa obtained from a local slaughterhouse. Cartilages and adhered tissues were removed completely, and the mucosal membrane was washed with PBS, pH 6.4 (Carvalho et al., 2013) . The receptor compartment was filled with medium, volume 12.0 mL (PBS, pH 6.4, containing 2.0% Polysorbate 80), maintained at 34°C by a circulating bath. A small magnetic bead was placed in the receptor compartment for stirring the medium at 400 rpm. Freshly excised porcine mucosa tissue (1.77 cm 2 ) was kept in PBS, pH 6.4, for 15 min to equilibrate, and then fixed to the diffusion cell. Receptor and donor compartments were tightly closed with a stainless steel clip. A comparative nasal diffusion study was performed by placing in the donor compartment 0.3 mL of KPF-NE, KPF-MNE or pure KPF suspension (1.0 mg/mL in water) maintaining the sink conditions for the assay (n = 4). After 6 h, 1 mL of receptor medium was withdrawn and filtered with a membrane filter of pore size 0.45 µm before analysis by HPLC. To analyze the KPF retained on the porcine nasal mucosa, the tissue was removed from the Franz cell and cleaned using a cotton swab. Then, the tissue was cut into small pieces, placed in test tubes with methanol and sonicated in an ultrasonic bath for 90 min. Samples were passed through a 0.45 µm membrane filter before analysis by HPLC.
Preliminary nasal toxicity studies
Nasal toxicity studies were carried out using freshly isolated porcine nasal mucosa collected from a local slaughterhouse (Carvalho et al., 2013) . Each mucosa piece, of uniform thickness, was treated with KPF-NE, KPF-MNE, blank nanoemulsions, PBS pH 6.4 (as negative control), or isopropyl alcohol (as positive control). After treatment for 1 h, pieces of mucosa were washed with PBS and fixed in 10% v/v formalin solution overnight and embedded in paraffin. The sections (5 µm) were cut using a microtome, stained with hematoxylin-eosin and observed under the microscope (Nikon Eclipse TE 300) to evaluate any damage to the mucosa (Shah et al., 2016) .
Measurement of ex vivo mucoadhesive strength
Mucoadhesive strength of formulations was evaluated by Texture analyzer (TA.XT.Plus, Stable Micro Systems, Surrey, UK) using freshly isolated porcine nasal mucosa (Shah et al., 2016) . A cleaned piece of nasal mucosa was immersed in artificial nasal mucus (ANM) for 30 s prior to the test; excess ANM was removed with soft paper. ANM was prepared by dispersing 8% (w/v) of mucin type II from porcine stomach in a solution of 7.45 mg/mL NaCl, 1.29 mg/mL KCl and 0.32 mg/mL CaCl 2 ·2H 2 O (Callens et al., 2003) . Pieces of mucosa were attached both onto the base of the texture analyzer and onto the probe using twosided adhesive tape. Each formulation (0.5 mL) was placed on the mucosa on the lower surface of the base. The mobile arm was lowered at a rate of 0.5 mm/s (pre-test speed) until contact with formulation was made. A contact force of 10 g was maintained for 150 s; subsequently, the probe was withdrawn from the membrane at a post-test speed of 0.1 mm/s. After an adhesive bond was formed, the strength (g) and the work of mucoadhesion (area under the force vs distance curve) (g.s) needed for detachment was registered. The acquired data was processed with Texture Exponent Lite software.
In vivo quantification of KPF in rat's brain
Animal experiments were conducted with prior approval from the Ethical Committee of the Universidade Federal do Rio Grande do Sul (Protocol # 31216) and performed according to the guidelines of "Principles of Laboratory Animal Care" from the National Institutes of Health (NIH).
Wistar rats (n = 4/group, weight: 300-400 g) were anesthetized with isoflurane before intranasal administration. Then, animals were placed in a supine position and treated with KPF-NE, KPF-MNE or KPF solution (KPF-S). KPF-S (KPF at 1.0 mg/mL) was prepared by solubilizing the drug in a mixture of 3% DMSO in PBS. Formulations were gently administered into each nostril (50 μL) with the help of a micropipette (equivalent to 100 µg of kaempferol per animal). After 1 h, the animals were decapitated and the whole brain was removed and washed twice using normal saline to remove adhering tissue/fluid. Subsequently, brain homogenates were obtained by homogenizing the tissues with 3 mL of methanol per g of tissue using IKA® Ultra-Turrax T8 mixer (IKA® Works Inc., NC, USA) at 9500 rpm for 1 min, and sonicated in an ultrasonic bath for 30 min. After centrifugation at 10,000 rpm at 4°C for 15 min, the supernatant was filtered at 0.45 µm and analyzed for drug content using HPLC.
Maintenance of cell lines
The C6 rat glioma cell line was obtained from American Type Culture Collection (ATCC) (Rockville, Maryland, USA). Cells at passage 5-30 were grown and maintained in 1% Dulbecco's modified Eagle's medium (DMEM) containing antibiotics (0.5 U/mL penicillin/streptomycin) and supplemented with 5% (v/v) fetal bovine serum (FBS). Cells were kept at 37°C, a minimum relative humidity of 95%, and an atmosphere of 5% CO 2 .
Assessment of glioma cell viability
The C6 glioma cells were seeded at 25 × 10 3 cells per well in DMEM 5% FBS in 24-well plates and allowed to grow until reaching semiconfluence. Glioma cells were treated with 1.0 µM of free KPF, KPF-NE or KPF-MNE for 72 h. Cells treated with 0.5% dimethyl sulfoxide (DMSO) or formulations without drugs were used as vehicle controls. After 72 h of treatment, the medium was removed. Cells were washed twice with 200 µL PBS, and 100 µL of 0.05% trypsin/EDTA solution was added to detach the cells, which were counted immediately in a hemocytometer by the Trypan blue dye exclusion test. Live cells that have intact membranes exclude the dye, whereas dead cells do not and are 
Cellular uptake of kaempferol
For evaluation of KPF cellular uptake, cells were treated with KPF-MNE or free KPF at 5 µM. After 48 h of incubation, the medium was aspirated and the cells were washed twice with ice-cold PBS, and scraped. Protein concentration was determined using the BCA Protein Assay kit. KPF was extracted from the cells with 200 µL of methanol containing 1% acetic acid by sonication for 1 min. Samples were filtered at 0.45 µm, and 20 μL was injected into the HPLC system for determining the concentrations of KPF (Bandaruk et al., 2014; Liu et al., 2006) .
Cell-cycle analysis
Cells were plated in 6-well plates, and after reaching semi-confluence, and treated with 1.0 µM of free KPF or KPF-MNE for 72 h. Cells treated with 0.5% DMSO or MNE were used as vehicle controls. At the end of the treatment, the medium and the cells were harvested and centrifuged at 400×g for 6 min. Next, the supernatant was removed and the cells were washed twice with PBS (pH 7.4), centrifuged, and resuspended in 400 µL staining solution (3.5 mM trisodium citrate; 0.5 mM TRIS.HCl (pH 7.6); NP 40 0.1% (v/v); RNAse 100 µg/mL; PI 50 µg/mL) at a concentration of 10 6 cells/mL. After 15 min, the cells were analyzed using flow cytometry (FACS Calibur cytometry system, FACS Calibur, BD Bioscience, Mountain View, CA, USA). The data obtained were analyzed by FLOWJO® software.
Annexin V/PI assay
Apoptotic cells were quantified using an AnnexinV-FITC-propidium iodide (PI) double staining kit (BD Biosciences, San Diego, USA) according to the manufacturer's instructions. Cells were plated in 24-well plates and, after reaching semi-confluence, were treated with 1.0 µM of MNE-KPF or free KPF. Cells treated with 0.5% DMSO or MNE were used as vehicle controls. At the end of the treatment, the medium and the cells were harvested and centrifuged at 400×g for 6 min. Cells were washed twice in cold PBS (pH 7.4) and counted. Next, 10 5 cells were suspended in binding buffer containing FITC-conjugated AnnexinV and PI. The samples were mixed and incubated for 15 min at room temperature in the dark. Apoptotic and/or necrotic cells were quantified using a dual-color flow cytometry technique on a FACS Calibur cytometry system (FACS Calibur, BD Bioscience, Mountain View, CA, USA). The data obtained were analyzed by FLOWJO® software. Cells were classified as follows: live cells (Annexin−/PI−); early apoptotic (Annexin+/PI−); late apoptotic (Annexin+/PI+) and necrotic (Annexin−/PI+). A total apoptosis measurement was also performed (Annexin+/PI -plus Annexin+/PI+).
Statistical analysis
The experiments are expressed as mean ± standard deviation (SD). The significance of the differences was evaluated using one-way ANOVA followed by Tukey's test. The statistical significance level was set at p < 0.05. All analyses were performed with GraphPad Prism 5 software (GraphPad Software, USA).
Results and discussion
Characterization of nanoemulsions
The developed KPF nanoemulsions presented an uniform milky yellowish aspect (data not shown). The physicochemical characteristics of formulations are shown in Table 1 . Formulations showed nanoscale droplets with low polydispersity index. Nanosized droplets present greater surface area and high free energy, assuring faster and greater drug permeation through absorption barriers such as mucosal surfaces (Comfort et al., 2015) . The uniformity of droplet size in the nanoemulsions is indicated by the PDI value. The small PDI value found (< 0.2) indicates a narrow size distribution. The significant increase (p < 0.05) in globule size upon inclusion of chitosan (KPF-MNE and MNE) is attributed to the chitosan coating on the nanoparticle surface and the previous evaporation step. After evaporating but before adding chitosan, the globule size was 170.4 ± 4.1 nm (n = 3). Furthermore, TEM of formulations confirmed their spherical shape and nanometric size (Fig. 1) . Also, the globule size observed by TEM is highly comparable to the average globule size measured by photon correlation spectroscopy. Formulations without coating presented a negative zeta potential, due to phospholipids and free fatty acids from egg lecithin. The addition of chitosan conferred a positive zeta potential to the globules.
The refractive index was measured to evaluate the isotropic nature of the nanoemulsions, as the value of the refractive index is helpful to show the chemical interactions between the drug and excipients. No significant difference in the RI values was observed between the KPF-NE and blank NE, and between KPF-MNE and blank MNE, indicating that the nanoemulsion and mucoadhesive formulations were chemically stable and remained isotropic in nature.
KPF-NE and KPF-MNE showed pH values of 4.70 ± 0.02 and 5.56 ± 0.02, respectively, which is well tolerated within the limits of human nasal pH range (4.5-6.5) and therefore would not cause nasal irritation upon intranasal administration (Arora et al., 2002) .
The viscosity of a formulation may affect absorption across the nasal mucosa, since it is related to the residence time in the nasal cavity. Formulations with higher viscosity tend to stay longer on the mucosa and increase the residence time in the nasal cavity; however, higher viscosity may also result in delay in release of the drug from the carrier to the mucosal surface (Furubayashi et al., 2007) . KPF-NE showed viscosities of 2.23 ± 0.01 and 1.93 ± 0.02 cP at 25 and 34°C, respectively. KPF-MNE showed viscosities of 11.48 ± 0.13 and 8.98 ± 0.16 cP at 25 and 34°C, respectively. A Newtonian rheological behavior was demonstrated for the formulations, since they exhibited constant viscosity; that is, the shear stress was directly proportional to the shear rate and viscosity was independent of shear rate (see 
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Supplementary Data, Fig. S1 and S2). As expected, the low viscosity of KPF-NE was very close to that of water, and the addition of chitosan increased considerably the viscosity of the system. The viscosity value of KPF-MNE may contribute to the high nasal absorption efficiency of KPF, according to the described relationship between formulation nasal absorption and viscosity, where moderate viscosity of the dosing formulation improved in vivo nasal absorption, while lower viscosity of the application decreased it, by mucociliary clearance (Furubayashi et al., 2007) .
KPF content and association efficiency (%AE)
The amount of KPF present in the KPF-NE and KPF-MNE was found to be 97.52 ± 2.88% and 96.37 ± 2.67%, respectively, for an initial content of 1 mg/ml, indicating a good recovery of KPF in the developed nanoemulsions. The aqueous solubility of pure KPF in water was 0.33 ± 0.04 µg/mL. The incorporation into nanoemulsion showed significant improvement in KPF solubility. Moreover, the association efficiency was determined by measuring the unentrapped drug present in the supernatant, which was obtained after centrifugation of the formulations. The %AE values of KPF-NE and KPF-MNE were 99.38 ± 0.06% and 99.35 ± 0.10%, respectively. As expected, considering KPF lipophilicity, a higher amount of KPF was found in the inner phase of all prepared formulations.
Ex vivo permeation studies
Ex vivo permeation studies were carried out using porcine nasal mucosa as a diffusional barrier to evaluate the permeation from the pure drug KPF and the developed formulations. KPF is a lipophilic drug with logP value of 3.11, with limited solubility in aqueous phase (Rothwell et al., 2005) . The solubility of a drug in the dissolution medium is essential to maintain sink condition. For this reason, KPF saturation solubility was determined in the receptor medium and was found to be 242.01 ± 7.49 µg/mL. As shown in Table 2 , KPF-MNE exhibited higher permeation compared to free KPF and KPF-NE. The significant increase in the amount of KPF that was able to reach the receptor fluid (p < 0.0001) may be attributed to the enhanced permeation activity of chitosan. This activity is due to the interaction of positively charged amino groups of chitosan with the anionic sites present in the mucous layers, mainly sialic acid, affecting the permeability of the epithelial membrane by the transient opening of the tight junctions in the epithelial cells of the mucosal barriers (Amidi et al., 2010; Vllasaliu et al., 2010 ). An advantage of using nanoparticle systems is that they provide a larger surface area for the interaction between the drug and the epithelial cells and, therefore, increasing the absorption through the nasal mucosa. Although the globule size is lower for KPF-NE, it has been observed that permeability is strongly related to the coating of the nanoparticle. Despite the addition of chitosan to the surface of the droplets increasing the mean diameter of KPF-MNE, KPF permeability was significantly higher in this system.
Another parameter analyzed in this study was the amount of KPF retained in the mucosa tissue after 6 h of experiment. The difference between the cumulative amount of retained KPF from KPF-NE and free-KPF was not statistically significant. On the other hand, there was a significant retention of KPF in the nasal mucosa when carried by mucoadhesive nanoemulsion, which could act as a deposit for its prolonged release (p < 0.0001). A justification for the lowest permeability of free KPF could be its hydrophobicity and incomplete solubilization in the solvent (Chao et al., 2012) . The enhanced permeation due to the addition of chitosan to the formulation compared to the corresponding nanoemulsion without chitosan was also observed in other works (Kumar et al., 2009; Sood et al., 2014) .
In vitro DPPH assay for antioxidant activity
KPF is reported to be an excellent antioxidant compound, with a potential role in the prevention and treatment of oxidative stress (Calderon-Montano et al., 2011; Devi et al., 2015) . The antioxidant capacity of KPF in the encapsulated form was assessed by the in vitro DPPH assay. The reduction capability of DPPH radicals was determined by the decrease in its absorbance at 515 nm, which is denoted by a purple color changing to yellow. As expected, a significant decrease in the concentration of the DPPH radical was observed due to the freeradical scavenging activity of KPF, even when incorporated into the nanoemulsion. As shown in Table 3 , the average percentages of DPPH obtained in KPF solution, KPF-MNE and KPF-NE were not statistically different (p < 0.05). Thus, the nanoemulsion did not compromise the inherent antioxidant activity of KPF.
Preliminary nasal toxicity studies
Nasal mucosa histopathology studies are useful to evaluate any potential toxic effects of a formulation on the integrity of the nasal mucosa. As shown in Fig. 2 , the mucosa treated with isopropyl alcohol (positive control) showed loss of epithelial cells, with internal tissue damage and shrinkage of the mucosal layer. The treatment with blank formulations, KPF-loaded formulations and PBS pH 6.4 (negative control) caused no structural damage, and the epithelial layer was intact, indicating that the excipients used in the formulations are biocompatible and safe for nasal administration. Nanoemulsion safety for nasal administration has already been widely demonstrated through nasal toxicity tests (Bshara et al., 2014; Cho et al., 2012; Shah et al., 2015; Sood et al., 2014 ).
Measurement of ex vivo mucoadhesive strength
As a predictor of the mucoadhesiveness of the proposed formulations, the mucoadhesion peak and the mucoadhesion work of the nanoemulsions were measured, which are the maximum force required to detach the material under study from the mucosal surface, and the work (applied total force) required for this, respectively.
As shown in Fig. 3 , KPF-MNE presented significantly higher values of strength (g) and mucoadhesion work (g.s) when compared to KPF-NE (p < 0.0001), and both formulations presented significant differences in comparison to the negative control (PBS) (p < 0.001).
The higher value of strength and mucoadhesion work for KPF-MNE compared to KPF-NE could be attributed to the presence of the mucoadhesion property of chitosan, indicating higher residence time at the site of absorption. The mucoadhesive property of the formulation depends on the presence of functional groups that allow mucoadhesion by interaction with mucin. For chitosan, a cationic polymer, the positive charge will allow binding and a strong electrostatic interaction with the negatively charged groups of sialic acid in the mucus present on the surface of the nasal mucosa, and hence the potential for a longer residence time (Bshara et al., 2014) .
In vivo quantification of KPF in rat's brain
To evaluate the brain targeting after a single dose via intranasal administration, a preliminary brain distribution of KPF in rats was investigated. The drug concentration (ng/g of tissue) in brain tissue after 1 h of nasal administration is given in Fig. 4 . Extraction efficiency from brain homogenate was found to be greater than 89.45% when analyzed by HPLC, using our previously validated method (Colombo et al., 2017) .
The concentration of KPF when loaded into KPF-MNE was found to be significantly higher compared to both KPF-S and KPF-NE (5-and 4.5-fold higher than KPF-S and KPF-NE, respectively). As is evident, the lower amount of KPF reaching the brain following intranasal administration of KPF-S and KPF-NE could be ascribed to rapid mucociliary clearance, as well as to nasal drainage. The use of nanoemulsions to improve nose-to-brain delivery of drugs is widely studied. The higher transport of a drug-loaded nanoemulsion from the nasal cavity to the brain is related to its small globule size, which allows the drug to be transported transcellulary through olfactory neurons to the brain via the various endocytic pathways of sustentacular or neuronal cells in the olfactory membrane (Comfort et al., 2015; Mistry et al., 2009 ). However, the formulation needs to contain an absorption enhancer and a mucobioadhesive agent for the maintenance of the drug at the site of absorption and to increase transport through the membrane. The addition of a mucoadhesive agent plays a key role in improving brain uptake as a result of the prolonged contact time of the applied formulation with the nasal mucosa (Comfort et al., 2015) . Furthermore, chitosan was reported as an absorption enhancer by its ability to open tight junctions in the olfactory and respiratory epithelia (Casettari and Illum, 2014; Vllasaliu et al., 2010) . Similar results were obtained by Kumar et al., (Kumar et al., 2008) , who showed the superior performance of a mucoadhesive nanoemulsion containing risperidone in comparison to the nanoemulsion without chitosan and to a simple risperidone solution, after intranasal administration.
To date, no study has been found that quantifies KPF in brain tissue after intranasal administration of KPF-loaded mucoadhesive nanosystems. The first study that proposed the intranasal administration of KPF was recently reported by our research group (Colombo et al., 2017) . In our results, the nanoemulsion containing chitosan allowed a significantly better transport of KPF into the brain. This result is in agreement with the results obtained from viscosity, ex-vivo mucoadhesive strength and ex vivo permeation studies, wherein the formulation with suitable viscosity for nasal administration and the highest mucoadhesion exhibited higher permeation and higher uptake into the brain.
Assessment of glioma cell viability
In order to determine the antitumor activity of the formulations, rat glioma C6 cells were treated with free KPF, KPF-NE, KPF-MNE (all at 1.0 µM) and blank formulations. After 72 h of incubation, a Trypan blue dye exclusion test was used to evaluate cell viability. The percentage of cell viability was calculated in relation to untreated cells considered as 100% viable. As shown in Fig. 5A , KPF-MNE caused a significant decrease in cell viability compared to all other treatment groups. The increased cytotoxic effect of KPF-MNE could be attributed to the better penetration of the drug into the glioma cells due to the positive charge of the carrier. Generally, positively charged nanoparticles exhibit better association with cells, as a result of attractive interactions with the negatively charged cell membrane, leading to a greater uptake rate, and, thus, greater cytotoxicity. Moreover, the small size of the nanoparticles facilitates their uptake by the cells (Hillaireau and Couvreur, 2009) . Chitosan presents the ability to facilitate the active transport of nanoparticles via absorptive mediated transcytosis, and chitosan-coated nanoparticles have been extensively used as carriers for tumor targets (Anitha et al., 2012; Chuah et al., 2014; Liu et al., 2012; Yang et al., 2015; Zhu et al., 2009) . Interestingly, for the cells treated with blank formulation and 1.0 µM KPF in solution, a significant decrease in cellular viability was not observed, evidencing the importance of the encapsulation of KPF in the nanosystem. To a lower extent than KPF-MNE, the unloaded nanoformulations also decreased cell viability after 72 h of treatment in relation to untreated cells. This effect may be explained by the physical interaction between the formulation and the cells, allowing them to be detached from the plate. Cytotoxicity is often due to many factors, such as the size, shape, composition, surface charge, and surface hydrophobicity of the nanoparticles (Frohlich, 2012) . In order better to understand the mechanisms underlying the anticancer effect, and based on its promising result, we selected KPF-MNE for further analysis of cell-cycle progression and apoptosis induction. As shown in Fig. 5B , the percentage viability of C6 cells decreased when treated with KPF at concentrations of 0.25 to 1.0 μM for KPF-MNE and 1 to 20 μM for free KPF. The IC50 for free KPF was 17.94 ± 5.41 µM, and for KPF-MNE it was 0.84 ± 0.15 µM. Furthermore, time-dependent stability of KPF-MNE were demonstrated under cell culture conditions (see Supplementary Data, Fig. S3 ).
Cellular uptake of kaempferol
For evaluation of cellular uptake, we tested different approaches with some limitations: after 24 h of treatment, KPF was detectable neither for KPF nor for KPF-MNE treatment. Treatment for 72 h resulted in significant death, and it was not possible to quantify the remaining cells. The treatment concentration of 5 µM was chosen since when it was treated at 1 µM, KPF was below the limit of quantification by HPLC.
Thus, KPF and KPF-MNE were added at 5 µM for 48 h of treatment.
Results showed that cellular content of KPF carried by mucoadhesive nanoemulsion achieved 4.40 ± 1.5 nmol/mg protein. On the other hand, when cells were treated with free KPF, KPF was not detectable by HPLC analysis. No interfering peaks were observed within the time frame in which KPF is detected. Blank cell samples did not demonstrate any interference peaks. Therefore, considering the IC50 values, the cytotoxicity of KPF-MNE in GBM is about 20-fold greater than free KPF (Fig. 5B) as result of higher cellular uptake when KPF is loaded into a mucoadhesive nanoemulsion.
Cell-cycle analysis
Considering that KPF-MNE inhibits cell growth in C6 cells, we decided to evaluate whether this inhibition effect could be due to an arrest of cell-cycle progression. Flow cytometry analysis showed that KPF-MNE did not alter the DNA content after treatment (Fig. 6 ), indicating that it did not affect the cell-cycle progression. Despite studies indicating that exposure to KPF resulted in cell-cycle arrest in different tumor cell lines (Cho and Park, 2013; Choi and Ahn, 2008; Dang et al., 2015; Song et al., 2014) , there were no differences among free KPF, MNE, free KPF + MNE and KPF-MNE at 1 µM after 72 h. It is a important finding, since cell-cycle arrest could be a reason for the failure of chemotherapy, where, after finishing the treatment, cancer cell may restore their proliferation capability (Silva et al., 2016) .
Annexin V/PI assay
To verify whether KPF-MNE could induce apoptotic or necrotic cell death, glioma cells were treated with KPF 1.0 µM for 72 h and AnnexinV-PI assay was carried out by flow cytometry analysis. KPF-MNE did not increase PI incorporation in C6 cells, indicating the absence of necrotic cell death (data not shown). However, treatment of glioma cells with KPF-MNE promoted a significant increase in early apoptosis content (EA = 15.1 ± 4.2%) and late apoptosis (15.2 ± 6.2%) as shown in Fig. 7E . Overall, KPF-MNE induced 30.4 ± 8.4% apoptosis after treatment (total apoptosis, Fig. 7F ). Free KPF (KPF) did not increase apoptosis at 1 µM, confirming the higher cytotoxic potential of KPF-MNE. Treatments with MNE, MNE + KPF or DMSO did not show significant alterations in apoptotic cell death either (Fig. 7A-D) .
Kaempferol is known to induce apoptosis in numerous cancer cell lines (Chen and Chen, 2013) . In vitro, KPF has been described to induce apoptosis in glioma cells by elevating intracellular oxidative stress by a decrease in the levels of redox active proteins SOD-1 and TRX-1, which are involved in maintaining cellular redox balance and through caspase-dependent mechanisms (Jeong et al., 2009; Sharma et al., 2007) . Seibert and collaborators (Seibert et al., 2011) have shown that cytotoxicity from KPF was not due to H 2 O 2 generation in the culture medium. Importantly, concentrations of KPF protecting glioma cells under oxidative stress were identical to those causing cell damage under normal conditions (in the absence of oxidative stress) (Ruweler et al., 2008) .
In addition to the antiproliferative effect, our results showed the ability of KPF-MNE to induce apoptosis in glioma cells at concentrations as low as 1.0 µM and to a greater extent than other studies that used free KPF (Jeong et al., 2009; Seibert et al., 2011; Sharma et al., 2007; Siegelin et al., 2008) .
Conclusions
Kaempferol-loaded nanoemulsions and mucoadhesive nanoemulsions were successfully prepared via a high-pressure homogenization technique, and showed nanometric globule size, high loading capacity and entrapment efficiency, and were able to preserve their antioxidant potential. Furthermore, the developed nanoemulsions showed no toxicity towards nasal mucosa. Ex vivo permeation studies and in vivo biodistribution studies confirmed the superiority of the developed chitosan-coated nanoemulsion for brain targeting after intranasal administration compared to KPF-NE and free KPF. The mucoadhesive nanoemulsion decreased the viability of glioma cells by enhancing apoptosis, a goal for cancer treatment.
Taken together, KPF-MNE seems to be a promising approach for nose-to-brain delivery of KPF and hence provides an important therapeutic candidate for pre-clinical glioma treatment. Pesquisa do Rio Grande do Sul -FAPERGS (Edital PqG 2017 -T.O. 17/ 2551-0001). The authors would also like to thank these agencies for their research fellowships.
